BOEHRINGER-INGELHEIM
27.10.2021 14:02:06 CEST | Business Wire | Press release
Boehringer Ingelheim and the Institute of Psychiatry, Psychology & Neuroscience (IoPPN) at King’s College London today announced a new collaboration focused on understanding the malfunctions in brain circuits that drive impaired cognition in people with major depressive disorder (MDD) and schizophrenia (SZ). The study will aim to connect individual symptoms to specific brain-circuit dysfunctions, and will inform the development of novel therapies that target the underlying neurobiological processes of individual behavioral traits.
“We are delighted to collaborate with King’s IoPPN, a leading institute for research in psychiatry”, said Dr Vikas Mohan Sharma, Head of Medicine CNS, Retinopathies & Emerging Areas at Boehringer Ingelheim. “This collaboration will advance our understanding to better assess cognition and those biomarkers linked to cognitive deterioration in people with major depressive disorder and schizophrenia. We look forward to jointly creating opportunities to accelerate future clinical trials and the development of treatments for the many people impacted by psychiatric disorders.”
The partners plan to conduct four clinical studies to assess the behaviors of people with MDD and SZ in their home environments as well as during their study center visits where the activation of brain circuits triggered by cognitive tasks will be mapped. The unique study design includes, beyond standard clinical assessments, a battery of cognitive tasks, functional magnetic resonance imaging (fMRI), electroencephalography (EEG), polysomnography, patient functioning assessment through virtual reality tools and digital biomarkers to monitor speech and sleep habits.
“King’s College London has a long-standing focus on advancing the understanding of brain circuits responsible for cognition deficits in both psychiatric and neurological disorders,” said Professor Steven Williams, project lead and Head of Department of Neuroimaging at King’s IoPPN. “Working with Boehringer Ingelheim, a research-driven company with vast experience in central nervous system drug discovery and clinical development, will allow us to enlist their expertise in clinical study design, enable new therapeutic concepts and better clinical trials of individual patient populations.”
Neuropsychiatric disorders affect hundreds of millions of people worldwide and can impact people’s health and their ability to learn and work. Cognition is a fundamental aspect of everyday life, including problem-solving, memory and attention. When affected, people living with poor cognition can have a reduced mental ability to process information, remember straightforward things or perceive other people’s emotions and expressions. These malfunctions are common across many forms of mental disorders. Although antipsychotic medications have evolved in the 1990s since their introduction, treatment options have otherwise remained mostly unchanged. This is at least partly due to the lack of breakthrough therapies to treat severe mental health issues. Finding solutions for cognitive impairment is a key area of Boehringer Ingelheim’s innovative mental health research. The company has built a comprehensive development program in this area including two ongoing phase II trials and a recent first-of-its-kind phase III start for its novel glycine transporter-1 (GlyT1) inhibitor. The clinical study of GlyT1 is an example for the potential development of new therapeutic concepts based on better understanding of which brain circuits are relevant for cognitive impairment associated with schizophrenia.
Boehringer Ingelheim’s Intended Audiences Notice
This press release is issued from our Corporate Headquarters in Ingelheim, Germany and is intended to provide information about our global business. Please be aware that information relating to the approval status and labels of approved products may vary from country to country, and a country-specific press release on this topic may have been issued in the countries where we do business.
Please click on the following link for ‘Notes to Editors’ and ‘References’:
http://www.boehringer-ingelheim.com/press-release/collaboration-kings-college-london
View source version on businesswire.com: https://www.businesswire.com/news/home/20211027005533/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Just 4.7% of Financial Institutions Continuously Update Their Compliance Monitoring and Controls as Risk Changes, New Research Finds24.9.2026 15:04:00 CEST | Press release
As financial crime threats, regulations and transaction volumes evolve dynamically, most compliance programs remain built around periodic review SymphonyAI, a global leader in vertical AI product platforms, and AML Intelligence, the leading source of news and insight for the financial crime compliance community, today released the FinCrime Frontier 2026–27 Report, finding that most financial institutions still rely on periodic review cycles to manage financial crime risk, even as the threats and regulations they are meant to track continue to evolve dynamically. Based on the perspectives of more than 200 financial crime and compliance leaders, including senior leaders from major global financial institutions, the research finds that just 4.7% of financial institutions continuously update their compliance monitoring and controls as risk changes, while 56.8% have not adopted always-on compliance monitoring at all, are only exploring it, or remain at an early, pilot-stage level. The findi
SymphonyAI Introduces Symphony Risk Intelligence, an Agent-native Platform That Unlocks Always-on Compliance™ — the Catalyst for Transforming the Financial Crime Operating Model24.9.2026 15:04:00 CEST | Press release
New industry research finds just 4.7% of financial institutions continuously update their compliance monitoring and controls as risk changes, a gap regulators are now pushing institutions to close SymphonyAI today introduced Symphony Risk Intelligence (SRI), an enterprise-grade, agent-native platform built to unlock Always-on Compliance™. This is a critical shift from periodic to continuous risk and compliance management, in which institutions continuously reassess risk and adapt controls as regulations, threats and business activity change, rather than waiting for the next scheduled review. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260924914614/en/ Current approaches have reached their structural limits. The FinCrime Frontier 2026–27 Report, released recently by SymphonyAI and AML Intelligence, finds just 4.7% of financial institutions continuously update their compliance monitoring and controls as risk changes, and 76
Boomi Appoints Mike Hickman as Chief Financial Officer24.9.2026 15:00:00 CEST | Press release
Three-decade technology finance leader joins Boomi to scale global operations, bringing experience across IPO, take-private, and large-scale acquisition integration Boomi, the data activation company for AI, today announced the appointment of Mike Hickman as Chief Financial Officer. Hickman will lead Boomi's global finance and accounting organization, spanning financial planning and analysis, accounting, treasury, tax, and financial reporting. He reports to Boomi Chairman and Chief Executive Officer Steve Lucas. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260924761566/en/ Boomi Appoints Mike Hickman as Chief Financial Officer Hickman brings three decades of senior finance leadership in high-growth SaaS and technology companies, with experience across the full corporate lifecycle: scaling through IPO, executing a take-private, and integrating large acquisitions. He joins from Proofpoint, where he spent seven and a half yea
Altasciences Supports 4B Healthcare in Advancing Steroid Nasal Irrigation Rinse to Clinical Trials24.9.2026 14:40:00 CEST | Press release
Altasciences is proud to announce that recent formulation work supporting 4B Healthcare Inc. (“4B”) has helped advance its RhineX nasal irrigation rinse therapy into clinical investigation. Following several months of formulation development, R&D manufacturing, stability testing, and quality assurance support at Altasciences’ CDMO facility in Harleysville, PA, the Tennessee-based pharmaceutical company has received FDA clearance to proceed with clinical testing of RhineX under its IND. First subject dosing is planned for October 2026, approximately seven months after formulation development began. "The concept for RhineX grew out of a problem I have seen in my own ENT practice for years—the need for a better treatment option for allergic rhinitis when conventional medical therapy is not enough,” said Brannon Mangus, MD, Co-Founder and CEO of 4B. “We founded 4B Healthcare to take that physician insight and turn it into a pharmaceutical product that could meaningfully change how these pa
ParaScript Acquired by Stakk to Create a Global Digital Trust Platform Focused on Combating Fraud24.9.2026 14:30:00 CEST | Press release
ParaScript’s AI-powered document intelligence technology integrates with Stakk’s SaaS platform to provide regulated organizations with a stronger defense against AI-driven digital identity fraud.Complementary technologies establish digital trust by continuously assessing identity, documents, behavior and context, making explainable decisions in milliseconds.Combined businesses serve more than 300 enterprise customers and processes more than 110 billion digital interactions annually across the U.S., Europe, the Middle East and Australia. ParaScript, an Al-powered document processing company, today announced that Stakk Limited (ASX: SKK) (“Stakk”), a company publicly traded on the Australian Stock Exchange (ASX), has successfully completed its US$63 million (A$88.7 million) acquisition of ParaScript, LLC and ParaScript Management, Inc. (“ParaScript”), creating a scaled and profitable AI-native digital trust platform. Stakk acquired ParaScript for its industry-leading AI-powered document
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom